Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02450643 · ClinicalTrials.gov registry record · NA
Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula
A NA study, sponsored by Société des Produits Nestlé (SPN).
- Completed
- Registry status
- NA
- Development phase
- 83
- Enrollment target
NCT02450643: Completed NA study, sponsored by Société des Produits Nestlé (SPN).
NCT02450643 is a NA study that has completed, run by Société des Produits Nestlé (SPN). The registered enrollment target is 83 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02450643, a NA study, has completed, sponsored by Société des Produits Nestlé (SPN).
- COMPLETED
- Registry status
- NA
- Development phase
- 83 participants
- Enrollment target
Study Summary
Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges (DBPCFC) of 2 extensively hydrolyzed formulas in random order. If both food challenges are passed, subjects will be asked to consume the Test formula in an at-home open challenge for 7 days.
Primary Outcome
number of children who react during a DBPCFC to either formula
Interventions
- OTHER Test extensively hydrolyzed formula
- OTHER Control extensively hydrolyzed formula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-06 |
| Phase | NA |
What the finished NCT02450643 record still lists
NCT02450643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Test extensively hydrolyzed formula is the first listed.
NCT02450643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02450643 about?
NCT02450643 is a clinical study titled "Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula". Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges (DBPCFC) of 2 extensively hydrolyzed formulas in random order. If both food challenges are passed, subjects will be asked to consume the Test formula in an at-home open challenge for 7 days...
What is the current status of trial NCT02450643?
This trial is currently completed. It is a NA study. The enrollment target is 83 participants. The study started on 2015-04. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02450643?
The interventions under investigation include: Test extensively hydrolyzed formula (OTHER), Control extensively hydrolyzed formula (OTHER).
Who is sponsoring clinical trial NCT02450643?
This trial is sponsored by Société des Produits Nestlé (SPN), which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02450643's enrollment target sits among peer trials
83 990th of 2000 higher than 1,011 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia